anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Glomerulomegaly and focal segmental glomerulosclerosis are histopathological hallmarks of obesity-related glomerulopathy (ORG). Podocyte injury and subsequent depletion are regarded as key processes in the development of these glomerular lesions in patients with ORG, but their impact on long-term kidney outcome is undetermined. Here, we correlated clinicopathological findings and podocyte depletion retrospectively in patients with ORG. Relative (podocyte density) and absolute (podocyte number per glomerulus) measures of podocyte depletion were estimated using model-based stereology in 46 patients with ORG. The combined endpoint of kidney outcomes was defined as a 30% decline in estimated glomerular filtration rate (eGFR) or kidney failure. Patients with lower podocyte density were predominantly male and had larger body surface area, greater proteinuria, fewer non-sclerotic glomeruli, larger glomeruli and higher single-nephron eGFR. During a median follow-up of 4.1 years, 18 (39%) patients reached endpoint. Kidney survival in patients with lower podocyte density was significantly worse than in patients with higher podocyte density. However, there was no difference in kidney survival between patient groups based on podocyte number per glomerulus. Cox hazard analysis showed that podocyte density, but not podocyte number per glomerulus, was associated with the kidney outcomes after adjustment for clinicopathological confounders. Thus, our study demonstrates that a relative depletion of podocytes better predicts long-term kidney outcomes than does absolute depletion of podocytes. Hence, the findings implicate mismatch between glomerular enlargement and podocyte number as a crucial determinant of disease progression in ORG.
Malignant glioma has a poor prognosis, despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant cycles of TMZ.  O6-methylguanine DNA methyltransferase  ( MGMT ) is a DNA repair enzyme which removes alkylated lesions from tumor DNA, thereby promoting chemoresistance. MGMT promoter methylation is a known predictor of temozolomide responsiveness; patients with unmethylated MGMT have a poorer prognosis. We employed deactivated Cas9-CRISPR technology to effectively target methylation in the vicinity of the MGMT methylation-specific polymerase chain reaction (MSP) region, as mediated by the catalytic domain of DNA methyltransferase DNMT3A. In doing so, we discovered that the selected dCas9/CRISPR-mediated methylation of certain regions of MGMT gene sequences can be used to enhance chemosensitivity in malignant glioma cells.
<P>PROBLEM TO BE SOLVED: To provide a therapy method associated with a MAdCAM (mucosal addressin cell adhesion molecule) to an inflammatory intestinal disease.  <P>SOLUTION: The antibody includes a human antibodies and an antigen-binding portion thereof that specifically binds to human MAdCAM and that functions to inhibit MAdCAM. The human anti-MAdCAM antibody and an antigen-binding portion thereof are provided. The antibody that is chimeric, bispecific, derivatized, a single strand antibody or a portion of a fusion protein is provided. The isolated heavy and light chain immunoglobulin derived from human anti-MAdCAM antibody and the nucleic acid molecule encoding such an immunoglobulin are provided. A method of making a human anti-MAdCAM antibody and a compositions comprising the antibody and a method of using the antibody and the composition for diagnosis and treatment are provided. A gene therapy method uses a nucleic acid molecule encoding the heavy and/or light chain immunoglobulin molecule that comprise the human anti-MAdCAM antibody.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Blood Flow Restriction plus Instability Resistance Training group. Participants will receive 2 sessions per week over 6 weeks.
Advise all patients to hydrate adequately before, during, and after the use of GaviLyte - H and bisacodyl delayed-release tablet, USP. If a patient develops significant vomiting or signs of dehydration after taking GaviLyte - H and bisacodyl delayed-release tablet, USP, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN). Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment.

Patients with electrolyte abnormalities should have them corrected before treatment with GaviLyte - H and bisacodyl delayed-release tablet, USP. In addition, use caution when prescribing GaviLyte - H and bisacodyl delayed-release tablet, USP for patients with conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.[See Drug Interactions ( 7.1)]
Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. 

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of VOLTAREN® GEL in patients with advanced renal disease. The renal effects of VOLTAREN® GEL may hasten the progression of renal dysfunction in patients with preexisting renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating VOLTAREN® GEL. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of VOLTAREN® GEL [see Drug Interactions (7)]. Avoid the use of VOLTAREN® GEL in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If VOLTAREN® GEL is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
PURPOSE:To improve processing rate of a liposome dispersion liquid having a specified particle diameter with a specified particle size distribution and containing a water-soluble material in the inner water phase by making the dispersion liquid permeate through a cellulose porous membrane. CONSTITUTION:A liposome dispersion liquid having 50-4000nm particle diameter with >=30% particle size distribution and containing a water-soluble material in the inner water phase is permeated by using a cellulose porous membrane. When the liposome dispersion liquid is permeated through the cellulose porous membrane, temp. is maintained lower than the phase transition temp. of the raw material lipid of liposome. Thereby, the processing rate of the liposome dispersion liquid can be improved. Further, by this method, liposome can be produced under the phase transition temp. of the raw material lipid and can be produced at high efficiency without causing changes in chemicals in the liposome or deterioration of liposome membrane.
This study examines the efficacy and safety of a 6 weeks memantine add-on to risperidon treatment for the prevention of cognitive dysfunction and negative symptomatology in patients with acute schizophrenia. The trail is double-blind, prospective, randomized, placebo-controlled, parallel-group and consisting of a 'placebo-run-in' period, treatment, and follow-up periods. Study personnel and participants were blinded to group assignment. In the 'run-in' period, patients received Lorazepam for the treatment of anxiety and tension states for two weeks before starting antipsychotic therapy. After the 'run-in' period treatment, patients began receiving antipsychotic therapy with Risperidon with continuous concomitant administration of Memantine, 20 mg/d, or placebo for six weeks. Adherence was assessed at each clinic visit by pill count. In cases of anxiety and tension states, an experienced psychiatrist decided whether patients should receive Lorazepam, 5 mg/d, as rescue medication in addition to the study medication (Memantine or placebo), to which the patients remained blinded. In cases of pseudo parkinsonism patients were allowed to receive Biperiden, up to 8 mg/d, and for the treatment of patients suffering from sleep disorders Zopiclon (15 mg/d) was allowed. The consumption of alcohol and drugs were not allowed during the trial. In both study parts, psychiatric assessments were performed at baseline as well as after 2; 4; 6; 12 and 24 weeks after treatment (that is, during the follow-up period). The neuropsychological examination was performed at baseline, and after 6 and 24 weeks. Psychiatric changes, adverse events, laboratory values, dose adjustments of the antipsychotic therapy, and possible pharmacologic adverse effects were systematically monitored throughout the study.
BACKGROUND: The relationships of serum neurofilament light chain (NfL) levels with chronic kidney disease (CKD) and renal function indicators remain controversial, and comprehensive studies with large sample sizes are lacking.
METHODS: In total, 2,051 participants aged 20 to 75 years were identified from the National Health and Nutrition Examination Survey (2013-2014 cycle). Logistic regression models were used to assess the associations between serum NfL levels and CKD, whereas multivariate linear models were used to investigate the relationships between serum NfL levels and two kidney function indicators, namely, estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR). Adjustments were made to account for potential confounding variables in the analysis. Subgroup analyses stratified by age and sex were conducted. When sNfL is incorporated into the model as continuous variables, a log transformation is applied.
RESULTS: The present study included a cohort of 2,051 individuals ranging in age from 20 to 75 years. After covariate adjustment, multivariable logistic regression revealed a significant association between high serum NfL levels and an increased prevalence of CKD (OR 1.60; 95% CI 1.40-1.82; p < 0.0001), which remained significant when analyzed by quartiles (p for trend <0.0001). There was a statistically significant inverse correlation between the serum NfL level and the eGFR (β=-6.34; 95% CI -8.32 to -4.37; p < 0.0001), as well as a positive correlation between the serum NfL level and the UACR (β = 84.67; 95% CI 19.52-149.83; p < 0.0001). Furthermore, when stratified by age, there were significant interactions of serum NfL levels with CKD, the eGFR, and the UACR (p for interaction = 0.008, 0.016, and 0.020, respectively).
CONCLUSION: Serum NfL levels are positively associated with the prevalence of CKD and the UACR but negatively correlated with the eGFR, particularly in older patients.
The study aims to evaluate the effect of yoga on the premenstrual syndrome, perceived stress level and the quality of life. The study was conducted as a randomized controlled trial at a university in Turkey. A yoga group = 39, a control group = 41, total of n = 80 female students participated in the study. In the study, firstly, the preview was made, then the yoga group was applied two days a week for eight weeks, the second follow-up was made after the application, and lastly, the last follow-up was made in the 24th week. Four questionnaire surveys were applied on students. When the yoga group compared with the control group in terms of premenstrual syndrome, the quality of life and perceived stress level in the 2nd follow-up, a statistically significant decrease was found in the mean between the menstrual and premenstrual period, and the quality of life increases in the yoga group compared to the control group students. Practicing yoga in university students with premenstrual syndrome reduced premenstrual symptoms and raised quality of life. Yoga can be recommended to girls with premenstrual syndrome (PMS) to reduce PMS and improve quality of life.
BACKGROUND: Carriers of the E40K loss-of-function variant in Angiopoietin-like 4 (ANGPTL4), have lower plasma triglyceride levels as well as lower rates of coronary artery disease (CAD) and type 2 diabetes (T2D). These genetic data suggest ANGPTL4 inhibition as a potential therapeutic target for cardiometabolic diseases. However, it is unknown whether the association between E40K and human diseases is due to linkage disequilibrium confounding. The broader impact of genetic ANGPTL4 inhibition is also unknown, raising uncertainties about the safety and validity of this target.
METHODS: To assess the impact of ANGPLT4 inhibition, we evaluated whether E40K and other loss-of-function variants in ANGPTL4 influenced a wide range of health markers and diseases using 29 publicly available genome-wide association meta-analyses of cardiometabolic traits and diseases, as well as 1589 diseases assessed in electronic health records within FinnGen (n = 309,154). To determine whether these relationships were likely causal, and not driven by other correlated variants, we used the Bayesian fine mapping algorithm CoPheScan.
RESULTS: The CoPheScan posterior probability of E40K being the causal variant for triglyceride levels was 99.99 %, validating the E40K to proxy lifelong lower activity of ANGPTL4. The E40K variant was associated with lower risk of CAD (odds ratio [OR] = 0.84, 95 % CI = 0.81 to 0.87, p=3.6e-21) and T2D (OR = 0.91, 95 % CI = 0.87 to 0.95, p=2.8e-05) in GWAS meta-analyses, with results replicated in FinnGen. These significant results were also replicated using other rare loss-of-function variants identified through whole exome sequencing in 488,278 participants of the UK Biobank. Using a Mendelian randomization study design, the E40K variant effect on cardiometabolic diseases was concordant with lipoprotein lipase enhancement (r = 0.82), but not hepatic lipase enhancement (r = -0.10), suggesting that ANGPTL4 effects on cardiometabolic diseases are potentially mainly mediated through lipoprotein lipase. After correction for multiple testing, the E40K variant did not significantly increase the risk of any of the 1589 diseases tested in FinnGen.
CONCLUSIONS: ANGPTL4 inhibition may represent a potentially safe and effective target for cardiometabolic diseases prevention or treatment.
PURPOSE: To obtain an antimicrobial agent comprising a diazonium group- containing aromatic or heterocyclic compound as an active ingredient, having effects especially on microorganisms having multiple medicine resistance, not showing toxicity to animal cells, having new action mechanism. CONSTITUTION: This antimicrobial agent comprises a diazonium group-containing aromatic or heterocyclic compound (e.g. 3-diazonium-1,2,4-triazole of the formula) as an active ingredient. The compound is preferably obtained by a well-known method for reacting an amino compound such as 3-amino-1,2,4-triazole corresponding to the diazonium group with 1 equivalent to an excessive amount of sodium nitrite in the presence of an acid such as hydrochloric acid. In the case of administering the objective antimicrobial agent by intramuscular injection or intravenous injection, a daily dose is 0.5-500mg per adult. In the case of scattering it as an agrochemical, the antimicrobial agent is diluted 1,000-1,000,000 times. In the case of administering to an animal, preferably a dose is 0.01-1,000mg per weight in the case of oral administration and 0.001-200mg in intramuscular administration.
Elucidating mechanisms by which early-life adversity (ELA) contributes to increased disease risk is important for mitigating adverse health outcomes. Prior work has found differences in immune cell gene expression related to inflammation and mitochondrial activity. Using a within-person between-group experimental design, we investigated differences in gene expression clusters across acute psychosocial stress and no-stress conditions. Participants were young adults (N = 29, aged 18 - 25 years, 62 % female, 47 % with a history of ELA). Gene expression was assessed in peripheral blood mononuclear cells collected at 8 blood draws spanning two 5-hour sessions (stress vs. no-stress) separated by a week, 4 across each session (number of observations = 221). We applied two unsupervised gene clustering methods - latent profile analysis (LPA) and weighted gene co-expression analysis (WGCNA) - to cluster genes with similar expression patterns across participants. LPA identified 11 clusters, 7 of which were significantly associated with ELA-status. WGCNA identified 5 clusters, 3 of which were significantly associated with ELA-status. LPA- and WGCNA-identified clusters were correlated, and all clusters were highly preserved across sessions and time. There was no significant effect of acute stress on cluster gene expression, but there was a significant effect of time, and significant differences by ELA-status. ELA-associated clusters related to RNA splicing/processing, inflammation, leukocyte differentiation and division, and mitochondrial activity were differentially expressed across time: ELA-exposed individuals showed decreased expression of these clusters at 90-minutes while controls showed increased expression. Our findings replicate previous work in this area and highlight additional mechanisms by which ELA may contribute to disease risk.
Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0. Treatment repeats every 8 to 12 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
Adequate water intake plays an important role in maintaining children's overall health, cognitive performance, fine motor skills and visual attention. It also plays a role in the maintenance of healthy weight. Many children do not consume sufficient water, especially in school. There is also potential that by providing enhanced access to water, there will be corresponding decreases in sugary beverage intake. Sugary beverages have been implicated as major contributors of excessive sugar and calorie intake in children, leading to multiple health concerns, such as type 2 diabetes, overweight and obesity, and dental caries. Schools are an optimal environment to increase children's water intake. Healthy hydration is a priority for Richmond Public School (RPS), as they recently adopted a new hydration policy into their school wellness policy, with hydration stations installed in all RPS schools. The purpose of this study is to determine the feasibility of a school-based hydration intervention. This study will pilot a school-based stakeholder-informed hydration intervention and examine its feasibility and preliminary efficacy.
Systems and methods of uploading image files of sensitive documents are disclosed to at least one trusted community of users. The trusted community may be an automated care pod used by medical providers to treat a patient. The image files may comprise the individual's patient records. A request for uploading may be made to the care pod and the care pod may generate a unique identifying symbol which is sent back to the sender. The care pod or managing system may receive the image file with the unique identifying symbol embedded or associated with the image file. In another embodiment, an automated extractor/verifier may process the uploaded image data and extract user information. Said extracted user information may then be compared against patient information associated with the care pod. If extracted information and patient information do not match, an error flag may be sent.
During the study the patient will either receive tranilast (300mg twice a day) or a placebo drug for a period of seven days. The patient will then have a seven day break followed by another period of seven days in which the patient will receive the other medication.
In this group hemostasis will be achieved by exposure to diode laser (Biolase, epic X) of 940 nm. The laser energy will be introduced into the canal orifice through a 300 µm optical fiber at 2 W, in a contact mode with continuous mode CW(According to the user manual('EpicX_CAN_UM.pdf', no date) for 1 second at each orifice for three times to achieve complete hemostasis. During laser application patients, operator and assistant will use protective eye shields according to the safety measures of the device user manual.
The invention discloses shampoo. The shampoo is prepared from traditional Chinese medicine extract and water. The shampoo comprises, by weight, 5-15 parts of Chinese angelica, 15-40 parts of leaf of Platycladus orientalis, 10-25 parts of the root bark of shaggy-fruited dittany, 20-50 parts of radix sophorae flavescentis, 15-30 parts of Chinese honey locust, 15-35 parts of tea seed cake, 5-10 parts of fleece-flower root, 2-10 parts of ginger, 20-60 parts of water and 2-5 parts of mulberry bark. The shampoo is prepared from pure natural traditional Chinese medicine materials, is prepared by simple processes, is mild, can remove dirt, can be rinsed easily and does not produce irritation on the skin. Through use of the shampoo, the hair is bright, smooth, elastic and fresh and can be combed easily. The shampoo has effects of removing dandruff and relieving itching. Through frequent use of the shampoo, the hair is bright and black.
Group of participants (n=10) allocated to this group will receive chlorhexidine varnish which will be applied according to the manufacturer's recommendations. Participants will be subjected to this treatment right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
The present invention relates to a Chinese medicine for treating chronic bronchitis, which is prepared from proved clinical recipe and composed of 200g of trichosanthes seed frost, 50g of perilla fruit, 50g of almond, 50g of white mustard seed, 50g of tendrilleaf fritillary bulb, 50g of semen, 50g of lily bulb, 50g of cortex mori radices, 50g of thinleaf milkwort root, 40g of radish seed, 40g of gecko, 40g of tokay gecko, 40g of Chinese caterpillar fungus, 40g of ophiopogon root, 20g of Chinese date, 200g of honey, 200g of malt sugar, 400g of pear juice and 300g of black sand sugar. The present invention has the efficiencies of cough relieving, phlegm dispersing, asthma relieving and vital energy consolidating, and is particularly good at eliminating lung wet trembling sound of chronic bronchitis patients. The present invention is used for treating 106 chronic bronchitis patients if prepared into oral pills, patients take one pill every time and take two times every day, one treatment period is thirty days, and the present invention and sensitive antibiotic are used for treatment in the acute attack period. The effective rate reaches 100%, and the present invention is safe and does not have toxic side effect. If chronic bronchitis patients stick to take medicine for one treatment period every year, the recurrence and aggravation of chronic bronchitis can be prevented to fundamental fundamentally reach the effect of clinical radical cure. Compared with the existing domestic clinical data, the present invention has obvious advantage of therapeutic effect, and recipes of which the therapeutic effect is identical to the therapeutic effect of the Chinese medicine does not exist.